Pharming Group (PHAR) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.02
- EPS estimate
- $0.06
- EPS surprise
- −68.25%
- Revenue surprise
- −9.36%
- Revenue
- $90.2M
- Revenue estimate
- $99.5M
- Reported
- Jul 30, 2026
Pharming Group reported Q2 2026 results on July 30, 2026. Earnings per share were $0.02, below the $0.06 estimate by 68.25%. Revenue came in at $90.2 million, short of the $99.5 million consensus by about 9.4%. Compared with Q2 2025, EPS fell from $0.06 and revenue slipped about 3% from $93.2 million.
Over the longer record, revenue has grown while profits have swung between small gains and losses. Full-year revenue rose from $245.3 million in 2023 to $297.2 million in 2024 and $376.1 million in 2025. Annual EPS stayed near break-even: a loss of $0.19 per share in 2023, a loss of $0.18 in 2024 and a profit of $0.01 in 2025. The highest quarterly revenue in the table is Q4 2025's $106.5 million. First quarters have often been weak, with losses in Q1 of 2023, 2024, 2025 and 2026. Across the 18 quarters shown, Pharming beat the EPS estimate nine times and missed nine times.
Pharming reported third-quarter results between October 24 and November 6 in each of the past three years. That points to late October or early November 2026 for the next report, which will show whether the company stays profitable after the first-half swing.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 30, 2026 | $0.06 | $0.02 | −68.25% | $90.2M | SEC |
| Q1 2026 | May 7, 2026 | $0.00 | −$0.07 | −7100.00% | $72.4M | SEC |
| Q4 2025 | Mar 12, 2026 | $0.02 | $0.07 | +366.67% | $106.5M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.00 | $0.10 | +2122.22% | $97.3M | SEC |
| Q2 2025 | Jul 31, 2025 | −$0.11 | $0.06 | +157.14% | $93.2M | SEC |
| Q1 2025 | May 8, 2025 | −$0.03 | −$0.22 | −780.00% | $79.1M | SEC |
| Q4 2024 | Mar 13, 2025 | $0.02 | $0.05 | +163.16% | $92.7M | SEC |
| Q3 2024 | Oct 24, 2024 | −$0.00 | −$0.02 | −700.00% | $74.8M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.00 | −$0.02 | −900.00% | $74.1M | SEC |
| Q1 2024 | May 8, 2024 | $0.01 | −$0.19 | −2814.29% | $55.6M | SEC |
| Q4 2023 | Mar 14, 2024 | $0.00 | −$0.04 | −988.89% | $81.2M | SEC |
| Q3 2023 | Oct 26, 2023 | −$0.13 | $0.01 | +103.85% | $66.7M | SEC |
| Q2 2023 | Aug 3, 2023 | −$0.10 | $0.01 | +110.34% | $54.9M | SEC |
| Q1 2023 | May 11, 2023 | −$0.07 | −$0.17 | −161.54% | $42.5M | SEC |
| Q4 2022 | Mar 16, 2023 | $0.06 | −$0.21 | −472.73% | $54.6M | SEC |
| Q2 2022 | Aug 4, 2022 | $0.09 | $0.22 | +138.89% | $50.2M | — |
| Q1 2022 | May 12, 2022 | −$0.06 | $0.05 | +183.33% | $46.6M | — |
| Q4 2021 | Mar 17, 2022 | $0.00 | $0.02 | +328.57% | $52.8M | — |
Quarterly revenue
Frequently asked questions
When did Pharming Group (PHAR) last report earnings?
Pharming Group last reported on Jul 30, 2026, covering fiscal Q2 2026.
Did PHAR beat earnings estimates?
No. Pharming Group reported EPS of $0.02 for Q2 2026 against a $0.06 estimate — a 68.25% miss.
How much revenue did PHAR report last quarter?
Pharming Group reported $90.2M in revenue for Q2 2026, against a consensus estimate of $99.5M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.